Reviewing Trius Therapeutics (TSRX) and Jazz Pharmaceuticals PLC (JAZZ)
Trius Therapeutics (NASDAQ: TSRX) and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.
Valuation & Earnings
This table compares Trius Therapeutics and Jazz Pharmaceuticals PLC’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Jazz Pharmaceuticals PLC||$1.54 billion||5.54||$758.97 million||$6.45||22.02|
Jazz Pharmaceuticals PLC has higher revenue and earnings than Trius Therapeutics.
This table compares Trius Therapeutics and Jazz Pharmaceuticals PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jazz Pharmaceuticals PLC||25.69%||22.75%||9.14%|
Institutional & Insider Ownership
87.9% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for Trius Therapeutics and Jazz Pharmaceuticals PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jazz Pharmaceuticals PLC||0||5||16||0||2.76|
Jazz Pharmaceuticals PLC has a consensus price target of $182.38, indicating a potential upside of 28.44%. Given Jazz Pharmaceuticals PLC’s higher possible upside, analysts plainly believe Jazz Pharmaceuticals PLC is more favorable than Trius Therapeutics.
Jazz Pharmaceuticals PLC beats Trius Therapeutics on 8 of the 8 factors compared between the two stocks.
Trius Therapeutics Company Profile
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Receive News & Ratings for Trius Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trius Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.